CFCaitlin B. Finn

Caitlin B. Finn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Caitlin B. Finn has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Recurrence and surveillance intensity after prophylactic central neck dissection for papillary thyroid carcinoma: Long-term follow-up of a randomized trial

    by Caitlin B. Finn, Benjamin A.Y. Cher, Nicholas M. Druar, Alexandra Helbing, Travis Cotton, Megan K. Applewhite, Jesse Pasternak, Sarah C. Oltmann, Ana K. Islam, Vivek R. Sant, et al.

  • Readmission and Cost of Parathyroidectomy By Admission Status in Secondary Hyperparathyroidism

    by Jasmine Hwang, James Sharpe, Caitlin Finn, Amanda Bader, Luke Keele, Yuvaram Reddy, Douglas Fraker, Heather Wachtel, Rachel R. Kelz

    Key Points: Among patients with kidney failure treated with dialysis, 37% underwent parathyroidectomy in the outpatient setting. Significant differences exist between patients selected for inpatient versus outpatient parathyroidectomy. Risk-adjusted readmission rates are similar after inpatient or outpatient parathyroidectomy for secondary hyperparathyroidism. Background: Outpatient parathyroidectomy for secondary hyperparathyroidism of kidney disease is increasing. Reduced length of stay is often associated with higher rates of readmission. The safety of outpatient parathyroidectomy in this population must be evaluated given the morbidity and higher risk of post-parathyroidectomy hungry bone syndrome associated with kidney failure. In this study, we compare parathyroidectomy outcomes and costs by admission status in dialysis-dependent patients with secondary hyperparathyroidism. Methods: Adult patients on dialysis who underwent elective parathyroidectomy for secondary hyperparathyroidism were identified in the Healthcare Cost and Utilization Project State Inpatient and State Ambulatory Surgery Databases from five geographically diverse states (2013–2019). Patients were classified by admission status: inpatient and outpatient (overnight or same-day). The primary outcome was 30-day readmission. Secondary outcomes were parathyroidectomy-related complications and cost. Outcomes were compared by admission status using chi-squared tests and costs using median quantile regression. Balancing weights were used for adjustment. Forward selection with logistic regression was used to identify factors associated with readmission among outpatients. Results: Among 1267 study participants, 63% were inpatients. Among outpatients, 40% underwent overnight stay and 42% underwent same-day discharge. Inpatients were more likely to be younger, Black race, have nonprivate insurance, and increased comorbidities than outpatients ( P < 0.05). Overall readmission rate was 19%. Readmission was higher among inpatients (Inpatient: 22% versus Outpatient: 15%; P = 0.002). After balancing weights, adjusted 30-day readmission rate was similar between inpatients and outpatients (14% versus 15%; P = 0.79). Readmission was similar between overnight stay and same-day discharge (Unadjusted: 12% versus 15%; P = 0.47. Adjusted: 15% versus 15%; P = 0.97). Outpatients with parathyroid autotransplantation, anxiety disorder, autoimmune conditions, congestive heart failure, and moderate/severe liver failure had significantly increased odds of readmission after parathyroidectomy. Adjusted median costs varied significantly (Adjusted Inpatient: $9615 [Interquartile range (IQR), $6463–12,963] versus Outpatient: $6357 [IQR, $4966–8153]; P < 0.001; Adjusted Overnight: $6453 [IQR, $5551–7850] versus Same-day: $5526 [IQR, $4346–7187]; P < 0.001). Conclusions: Select patients with secondary hyperparathyroidism may undergo outpatient parathyroidectomy safely with reduced costs.

  • Disparities in Endocrine Surgery Care

    by Caitlin B. Finn, Rachel R. Kelz

  • Predicting cure and hypocalcemia by intraoperative parathyroid hormone decline in normohormonal primary hyperparathyroidism: A multi-institutional validation study

    by Timothy Kravchenko, Caitlin B. Finn, Douglas L. Fraker, Rachel R. Kelz, Carrie Cunningham, Heather Wachtel, Lauren N. Krumeich


  • Revisiting the Relationship Between Tumor Size and Risk in Well-Differentiated Thyroid Cancer

    by Sara P. Ginzberg, James Sharpe, Jesse E. Passman, Wajid Amjad, Christopher J. Wirtalla, Jacqueline M. Soegaard Ballester, Caitlin B. Finn, Susan J. Mandel, Rachel R. Kelz, Heather Wachtel

    Large tumor size is associated with poorer outcomes in well-differentiated thyroid cancer (WDTC), yet it remains unclear whether size >4 cm alone confers increased risk, independent of other markers of aggressive disease. The goal of this study was to assess the relationship between tumor size, other high-risk histopathologic features, and survival in WDTC, and to evaluate the significance of 4 cm as a cutoff for management decisions. Patients with WDTC were identified from the National Cancer Database (2010-2015) and categorized by tumor size [i.e., small (≤4 cm) or large (>4 cm)] and presence of high-risk histopathologic features (e.g., extrathyroidal extension). First, propensity score matching was used to identify patients who were similar across all other observed characteristics except for small vs. large tumor size, and a multivariable Cox proportional hazards model was used to estimate the relationship between tumor size and survival. Second, we assessed whether the presence of high-risk features demonstrate conditional effects on survival based on the presence of tumor size >4 cm using an interaction term. Finally, additional models assessed the relationship between incremental 1 cm increases in tumor size and survival. Analyses were repeated using a validation cohort from the Surveillance, Epidemiology, and End Results Program (2008-2013). Of 193,133 patients in the primary cohort, 7.9% had tumors >4 cm, and 30% had at least one high-risk feature. After matching, tumor size >4 cm was independently associated with worse survival (HR 1.63, p4 cm and one or more other high-risk features together yielded worse survival than either size >4 cm alone (MMD: 0.70, p<0.001) or other high-risk features alone (MMD: 0.49, p<0.001). When assessed in 1 cm increments, the largest increases in hazard of death occurred at 2 cm and 5 cm, not 4 cm. Results from the validation cohort were largely consistent with our primary findings. Concomitant high-risk features confer worse survival than large tumor size alone, and a 4 cm cutoff is not associated with the greatest increase in risk. These findings support a more nuanced approach to tumor size in the management of WDTC.


  • Inefficiencies of care in hub and spoke healthcare systems: A multi-state cohort study

    by Ezra S. Brooks, Caitlin B. Finn, Christopher J. Wirtalla, Rachel R. Kelz


  • The use and costs of same-day surgery versus overnight admission for total thyroidectomy: A multi-state, all-payer analysis

    by Caitlin B. Finn, James E. Sharpe, Lauren N. Krumeich, Sara P. Ginzberg, Jacqueline M. Soegaard Ballester, Jason K. Tong, Heather Wachtel, Douglas L. Fraker, Rachel R. Kelz


  • Open Access

    A Novel Mobile App to Identify Patients With Multimorbidity in the Emergency Setting: Development of an App and Feasibility Trial

    by Claire Barthlow Rosen, Sanford Eugene Roberts, Solomiya Syvyk, Caitlin Finn, Jason Tong, Christopher Wirtalla, Hunter Spinks, Rachel Rapaport Kelz

    Background: Multimorbidity is associated with an increased risk of poor surgical outcomes among older adults; however, identifying multimorbidity in the clinical setting can be a challenge. Objective: We created the Multimorbid Patient Identifier App (MMApp) to easily identify patients with multimorbidity identified by the presence of a Qualifying Comorbidity Set and tested its feasibility for use in future clinical research, validation, and eventually to guide clinical decision-making. Methods: We adapted the Qualifying Comorbidity Sets’ claims-based definition of multimorbidity for clinical use through a modified Delphi approach and developed MMApp. A total of 10 residents input 5 hypothetical emergency general surgery patient scenarios, common among older adults, into the MMApp and examined MMApp test characteristics for a total of 50 trials. For MMApp, comorbidities selected for each scenario were recorded, along with the number of comorbidities correctly chosen, incorrectly chosen, and missed for each scenario. The sensitivity and specificity of identifying a patient as multimorbid using MMApp were calculated using composite data from all scenarios. To assess model feasibility, we compared the mean task completion by scenario to that of the American College of Surgeons National Surgical Quality Improvement Program Surgical Risk Calculator (ACS-NSQIP-SRC) using paired t tests. Usability and satisfaction with MMApp were assessed using an 18-item questionnaire administered immediately after completing all 5 scenarios. Results: There was no significant difference in the task completion time between the MMApp and the ACS-NSQIP-SRC for scenarios A (86.3 seconds vs 74.3 seconds, P=.85) or C (58.4 seconds vs 68.9 seconds,P=.064), MMapp took less time for scenarios B (76.1 seconds vs 87.4 seconds, P=.03) and E (20.7 seconds vs 73 seconds, P<.001), and more time for scenario D (78.8 seconds vs 58.5 seconds, P=.02). The MMApp identified multimorbidity with 96.7% (29/30) sensitivity and 95% (19/20) specificity. User feedback was positive regarding MMApp’s usability, efficiency, and usefulness. Conclusions: The MMApp identified multimorbidity with high sensitivity and specificity and did not require significantly more time to complete than a commonly used web-based risk-stratification tool for most scenarios. Mean user times were well under 2 minutes. Feedback was overall positive from residents regarding the usability and usefulness of this app, even in the emergency general surgery setting. It would be feasible to use MMApp to identify patients with multimorbidity in the emergency general surgery setting for validation, research, and eventual clinical use. This type of mobile app could serve as a template for other research teams to create a tool to easily screen participants for potential enrollment.


  • Development of a Machine Learning Model to Identify Colorectal Cancer Stage in Medicare Claims

    by Caitlin B. Finn, James E. Sharpe, Jason K. Tong, Elinore J. Kaufman, Heather Wachtel, Cary B. Aarons, Gary E. Weissman, Rachel R. Kelz

    PURPOSE: Staging information is essential for colorectal cancer research. Medicare claims are an important source of population-level data but currently lack oncologic stage. We aimed to develop a claims-based model to identify stage at diagnosis in patients with colorectal cancer. METHODS: We included patients age 66 years or older with colorectal cancer in the SEER-Medicare registry. Using patients diagnosed from 2014 to 2016, we developed models (multinomial logistic regression, elastic net regression, and random forest) to classify patients into stage I-II, III, or IV on the basis of demographics, diagnoses, and treatment utilization identified in Medicare claims. Models developed in a training cohort (2014-2016) were applied to a testing cohort (2017), and performance was evaluated using cancer stage listed in the SEER registry as the reference standard. RESULTS: The cohort of patients with 30,543 colorectal cancer included 14,935 (48.9%) patients with stage I-II, 9,203 (30.1%) with stage III, and 6,405 (21%) with stage IV disease. A claims-based model using elastic net regression had a scaled Brier score (SBS) of 0.45 (95% CI, 0.43 to 0.46). Performance was strongest for classifying stage IV (SBS, 0.62; 95% CI, 0.59 to 0.64; sensitivity, 93%; 95% CI, 91 to 94) followed by stage I-II (SBS, 0.45; 95% CI, 0.44 to 0.47; sensitivity, 86%; 95% CI, 85 to 76) and stage III (SBS, 0.32; 95% CI, 0.30 to 0.33; sensitivity, 62%; 95% CI, 61 to 64). CONCLUSION: Machine learning models effectively classified colorectal cancer stage using Medicare claims. These models extend the ability of claims-based research to risk-adjust and stratify by stage.


  • Thyroid cancer pathologic upstaging: Frequency and related factors

    by Jacqueline M. Soegaard Ballester, Caitlin B. Finn, Sara P. Ginzberg, Rachel R. Kelz, Heather Wachtel